Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 6, 2018 (8 years ago)

Levoxyl (levothyroxine sodium tablets, USP)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent Drug.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01

Affected NDC 60793-0855-01

Compare with the code on your package — it is the most precise check available.

Drug: Levothyroxine Category: Thyroid Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Levoxyl
levothyroxine sodium
NDC 60793-0855
112 ug/1 Tablet
Oral
Pfizer Laboratories Div Pfizer Inc Rx
Recalling firm
Pfizer Inc.
NDC code
60793-855-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0339-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levothyroxine recalls

See all

Other recalls by Pfizer Inc.

All 2018 recalls